TABLE 4.

In vitro antimicrobial activity of 10 agents against macrolide-resistant Mycoplasma pneumoniae strains (n = 12)

StrainPatient age (yr)MIC (μg/ml)aNucleotide changes, 23S rRNAbPFGE patternc
ERYCLRAZMTELJOSMDMRKIMINLVXSFX
ARD-1761232323232480.25110.0625A2063GIIb
ARD-18510646432640.06250.03130.01560.50.50.0625NoneIIb
ARD-1909664643232440.250.06250.50.0313A2063GIIb
ARD-1940664646464220.03130.06250.50.0313A2063GI
ARD-19861064646464880.1250.12510.0313A2063GI
ARD-20009646464648640.1250.06250.50.0313A2064GI
ARD-20819>6416162>64>6480.50.50.0313A20634I
ARD-215911>64>64>64>64880.1250.1250.50.0313A2063GIIb
ARD-2313116464326464>64160.2510.0313A2063GI
ARD-231613>64>64>64>64880.1250.12510.0313A2063GI
ARD-23233>64>64644>64>64160.03130.50.0156A2064GIIb
ARD-238112>64>64>64>64880.1250.2510.0313A2063GI
  • a ERY, erythromycin; CLR, clarithromycin; AZM, azithromycin; TEL, telithromycin; JOS, josamycin; MDM, midecamycin; RKI, rokitamycin; MIN, minocycline; LVX, levofloxacin; SFX, sitafloxacin (DU-6859a).

  • b M. pneumoniae numbering.

  • c PFGE typing was classified into group I and subgroup II b as described by Cousin-Allery et al. (2).